Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network

Abstract

We sought to define trends in and predictors of carbapenem consumption across community, teaching, and university-affiliated hospitals in the United States and Canada. We conducted a retrospective multicenter survey of carbapenem and broad-spectrum noncarbapenem beta-lactam consumption between January 2011 and December 2013. Consumption was tabulated as defined daily doses (DDD) or as days of therapy (DOT) per 1,000 patient days (PD). Multivariate mixed-effects models were explored, and final model goodness of fit was assessed by regressions of observed versus predicted values and residual distributions. A total of 20 acute-care hospitals responded. The centers treated adult patients (n = 19/20) and pediatric/neonatal patients (n = 17/20). The majority of the centers were nonprofit (n = 17/20) and not affiliated with medical/teaching institutions (n = 11/20). The median (interquartile range [IQR]) carbapenem consumption rates were 38.8 (17.4 to 95.7) DDD/1,000 PD and 29.7 (19.2 to 40.1) DOT/1,000 PD overall. Carbapenem consumption was well described by a multivariate linear mixed-effects model (fixed effects, R2 = 0.792; fixed plus random effects, R2 = 0.974). Carbapenem consumption increased by 1.91-fold/quarter from 48.6 DDD/1,000 PD (P = 0.004) and by 0.056-fold/quarter from 45.7 DOT/1,000 PD (P = 0.93) over the study period. Noncarbapenem consumption was independently related to increasing carbapenem consumption (beta = 0.31 for increasing noncarbapenem beta-lactam consumption; P < 0.001). Regular antibiogram publication and promotion of conversion from intravenous (i.v.) to oral (p.o.) administration independently affected carbapenem consumption rates. In the final model, 58.5% of the observed variance in consumption was attributable to between-hospital differences. Rates of carbapenem consumption across 20 North American hospitals differed greatly, and the observed differences were correlated with hospital-specific demographics. Additional studies focusing on the drivers of hospital-specific carbapenem consumption are needed to determine whether these rates are justifiable.

Seeking patterns of antibiotic resistance in ATLAS, an open, raw MIC database with patient metadata

“…7 C) and we speculate doripenem’s increase might result from recommendations shifting to mitigate resistance in other carbapenems 54 – 56 . Consistent with this, a 2019 survey of 20 US hospitals shows while doripenem has more variable usage data, it was the most used carbapenem measured in days of treatment per patient day whose defined daily dosage was as high as half of the most-used carbapenem 57 , Tables 1 and 3.…”

Development of the predicted and standardized carbapenem usage metric: Analysis of the Japanese Diagnosis Procedure Combination payment system data

“…This metric was developed based on the Antimicrobial Use and Resistance Module utilized in the United States. Considering that the SAAR cannot be generalized to various geographical areas with different antimicrobial usage, a metric that evaluates antimicrobial use in each region is promptly needed [11]. The present study identified MDC Nos.4 (DDs of the respiratory system), which includes severe bacterial pneumonia, and 13 (DDs of the blood and blood forming organs and immunological disorders), which includes immunodeficiency such as febrile neutropenia, as strong contributors for increased carbapenem consumption.…”

Epidemiology of Nocardia Species at a Tertiary Hospital in Southern Taiwan, 2012 to 2020: MLSA Phylogeny and Antimicrobial Susceptibility

“…The higher rate of non-susceptibility of IPM observed in our study could either be a unique regional resistance profile of Nocardia spp. in southern Taiwan or selection pressure from the overuse of carbapenems [ 21 , 22 ]. This finding suggests that FEP and IPM should not be used empirically until the antimicrobial susceptibility results are available.…”